open access

Vol 10, No 2 (2014)
Other materials agreed with the Editors
Published online: 2014-05-14
Get Citation

An update on clinical trials of targeted therapies in thyroid cancer

Sigurdis Haraldsdottir, Manisha H. Shah
Onkol. Prak. Klin 2014;10(2):121-130.

open access

Vol 10, No 2 (2014)
Onkologia na świecie
Published online: 2014-05-14

Abstract

Purpose of review. Several new targeted therapies with multikinase inhibitors targeting vascular endothelial growth factor (VEGF), rearranged during transfection and v-raf murine sarcoma viral oncogene homolog B1 pathways have been tested in clinical trials for radioiodine-refractory differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC) in the past 10 years.

Recent findings. Results of the fi rst phase III trial of VEGF-targeted therapy (sorafenib) in DTC were presented in June 2013, and two phase III trials with VEGF and rearranged during transfection-targeted therapies (vandetanib and cabozantinib) in MTC have led to approval by US Food and Drug Administration in the past 2 years. Whereas such therapies increase median progression-free survival compared to placebo, there is no therapy proven to improve overall survival yet. Signifi cant potential adverse event risks associated with such therapies need to be recognized. Dissemination of knowledge about targeted therapies is critical for various medical specialists as patient care for thyroid cancers is best delivered in a multidisciplinary setting.

Summary. Successful development of targeted systemic therapies in DTC and MTC in the past 5 years is incredibly exciting in the fi eld and patients with advanced DTC/MTC now have new standard-of-care therapy options.

Abstract

Purpose of review. Several new targeted therapies with multikinase inhibitors targeting vascular endothelial growth factor (VEGF), rearranged during transfection and v-raf murine sarcoma viral oncogene homolog B1 pathways have been tested in clinical trials for radioiodine-refractory differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC) in the past 10 years.

Recent findings. Results of the fi rst phase III trial of VEGF-targeted therapy (sorafenib) in DTC were presented in June 2013, and two phase III trials with VEGF and rearranged during transfection-targeted therapies (vandetanib and cabozantinib) in MTC have led to approval by US Food and Drug Administration in the past 2 years. Whereas such therapies increase median progression-free survival compared to placebo, there is no therapy proven to improve overall survival yet. Signifi cant potential adverse event risks associated with such therapies need to be recognized. Dissemination of knowledge about targeted therapies is critical for various medical specialists as patient care for thyroid cancers is best delivered in a multidisciplinary setting.

Summary. Successful development of targeted systemic therapies in DTC and MTC in the past 5 years is incredibly exciting in the fi eld and patients with advanced DTC/MTC now have new standard-of-care therapy options.

Get Citation

Keywords

multikinase inhibitor, rearranged during transfection (RET), targeted therapy, thyroid cancer, v-raf murine, sarcoma viral oncogene homolog B1 (BRAF)

About this article
Title

An update on clinical trials of targeted therapies in thyroid cancer

Journal

Oncology in Clinical Practice

Issue

Vol 10, No 2 (2014)

Article type

Other materials agreed with the Editors

Pages

121-130

Published online

2014-05-14

Bibliographic record

Onkol. Prak. Klin 2014;10(2):121-130.

Keywords

multikinase inhibitor
rearranged during transfection (RET)
targeted therapy
thyroid cancer
v-raf murine
sarcoma viral oncogene homolog B1 (BRAF)

Authors

Sigurdis Haraldsdottir
Manisha H. Shah

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl